Clinical Trial Update: A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. [Phase 2]

View source ↗

Summary

A randomized Phase II study of SUBATM-itraconazole in untreated metastatic non-small cell lung cancer was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SUBATM-itraconazole (itraconazole)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2017-06-02